Oncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting
Hematologic Oncology Update
00:00
IDH2 and IDH1 - What's Your Take on That?
IDH2 disease is a little bit more resistant than IDH1 disease. The key distinction right now is there's two different drugs for each of those subtypes. There are subtle differences but I think they're more similar than different to be honest with you.
Transcript
Play full episode
